- Home
- VRTX vs INFY Comparison
VRTX vs INFY Comparison
Compare VRTX & INFY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRTX
- INFY
- Stock Information
- Founded
- VRTX 1989
- INFY 1981
- Country
- VRTX United States
- INFY India
- Employees
- VRTX N/A
- INFY N/A
- Industry
- VRTX EDP Services
- INFY EDP Services
- Sector
- VRTX Technology
- INFY Technology
- Exchange
- VRTX Nasdaq
- INFY Nasdaq
- Market Cap
- VRTX 115.6B
- INFY 96.0B
- IPO Year
- VRTX 1991
- INFY 1999
- Fundamental
- Price
- VRTX $436.00
- INFY $18.13
- Analyst Decision
- VRTX Buy
- INFY Hold
- Analyst Count
- VRTX 26
- INFY 7
- Target Price
- VRTX $512.54
- INFY $17.33
- AVG Volume (30 Days)
- VRTX 2.1M
- INFY 8.8M
- Earning Date
- VRTX 05-05-2025
- INFY 07-17-2025
- Dividend Yield
- VRTX N/A
- INFY 2.59%
- EPS Growth
- VRTX N/A
- INFY N/A
- EPS
- VRTX N/A
- INFY 0.76
- Revenue
- VRTX $11,099,700,000.00
- INFY $19,277,000,000.00
- Revenue This Year
- VRTX $10.36
- INFY $5.32
- Revenue Next Year
- VRTX $10.61
- INFY $7.39
- P/E Ratio
- VRTX N/A
- INFY $24.11
- Revenue Growth
- VRTX 8.98
- INFY 3.85
- 52 Week Low
- VRTX $377.85
- INFY $15.82
- 52 Week High
- VRTX $519.88
- INFY $23.63
- Technical
- Relative Strength Index (RSI)
- VRTX 39.81
- INFY 52.74
- Support Level
- VRTX $416.60
- INFY $17.81
- Resistance Level
- VRTX $448.00
- INFY $18.35
- Average True Range (ATR)
- VRTX 13.25
- INFY 0.25
- MACD
- VRTX -0.20
- INFY 0.02
- Stochastic Oscillator
- VRTX 37.85
- INFY 47.68
About VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
About INFY Infosys Limited
Infosys is a leading global IT services provider, with nearly 250,000 employees. Based in Bangalore, the Indian IT services firm leverages its offshore outsourcing model to derive 60% of its revenue from North America. The company offers traditional IT services offerings: consulting, managed services and cloud infrastructure services, and business process outsourcing as a service (BPaaS).